

International Journal of Molecular Veterinary Research, 2024, Vol. 14, No. 5
Received: 02 Apr., 2024 Accepted: 18 May, 2024 Published: 13 Jun., 2025
This study studys the potential and limitations of various animal models used in immunotherapy research, with a focus on genetically engineered immunodeficient mice, patient-derived xenografts (PDXs), and humanized mouse models. These models are instrumental in understanding the interactions between the immune system and tumors, and in preclinical testing of new immunotherapeutic agents. However, significant challenges remain, including species-specific differences that limit the translational relevance of these models to human clinical outcomes. Advances in humanized mouse models, which incorporate human immune cells and tumor tissues, offer promising avenues for more accurate preclinical assessments. Despite their potential, these models also face limitations such as incomplete immune system reconstitution and high costs. This study highlights the need for continued refinement of animal models to enhance their predictive power and translational applicability in cancer immunotherapy research.
. HTML
Associated material
. Readers' comments
Other articles by authors
. Qineng Si

Related articles
. Animal models

. Cancer immunotherapy

. Humanized mice

. Patient-Derived xenografts (PDXs)

. Preclinical studies

Tools
. Post a comment